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Outcomes in Mitral Regurgitation
Due to Flail Leaﬂets
A Multicenter European Study
Francesco Grigioni, MD, PHD,* Christophe Tribouilloy, MD, PHD, FACC,†
Jean Francois Avierinos, MD,‡ Andrea Barbieri, MD,§ Marinella Ferlito, MD,*
Faouzi Trojette, MD,† Laurence Tafanelli, MD,‡ Angelo Branzi, MD,*
Catherine Szymanski, MD,† Gilbert Habib, MD,‡ Maria G. Modena, MD,§
Maurice Enriquez-Sarano, MD, FACC, on behalf of the MIDA Investigators
Bologna and Modena, Italy; Amiens and Marseille, France; and Rochester, Minnesota
O B J E C T I V E S The purpose of this study was to assess incidence and predictors of events associated
with nonsurgical and surgical management of severe mitral regurgitation (MR) in European institutions.
B A C KG ROUND The management of patients with MR remains disputed, warranting multicenter
studies to deﬁne clinical outcome in routine clinical practice.
METHOD S The MIDA (Mitral Regurgitation International DAtabase) is a registry created for
multicenter study of MR with echocardiographically diagnosed ﬂail leaﬂet as a model of pure, organic
MR. Our cases were collected from 4 European centers. We enrolled 394 patients (age 64 11 years; 67%
men; 64% in New York Heart Association functional class I to II; left ventricular ejection fraction 67  10%).
R E S U L T S During a median follow-up of 3.9 years, linearized event rates/year under nonsurgical
management were 5.4% for atrial ﬁbrillation (AF), 8.0% for heart failure (HF), and 2.6% for death. Mitral
valve (MV) surgery was performed in 315 (80%) patients (repair in 250 of 315, 80%). Perioperative
mortality, deﬁned as death within 30 days from the operation, was 0.7% (n  2). Surgery during
follow-up was independently associated with reduced risk of death (adjusted hazard ratio [HR] 0.42, 95%
conﬁdence interval [CI] 0.21 to 0.84; p  0.014). Beneﬁt was largely driven by MV repair (adjusted HR vs.
replacement 0.37, 95% CI 0.18 to 0.76; p 0.007). In 102 patients strictly asymptomatic and with normal
ventricular function, 5-year combined incidence of AF, HF, or cardiovascular death (CVD) was 42  8%.
In these patients, surgery also reduced rates of CVD/HF (HR 0.26, 95% CI 0.08 to 0.89; p  0.032).
CONC L U S I O N S In this multicenter study, nonsurgical management of severe MR was associated
with notable rates of adverse events. Surgery especially MV repair performed during follow-up was
beneﬁcial in reducing rates of cardiac events. These ﬁndings support surgical consideration in patients
with MR due to ﬂail leaﬂets for whom MV repair is feasible. (J Am Coll Cardiol Img 2008;1:133–41)
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134itral regurgitation (MR) is one of the
most frequent valve lesions, both in
Europe (1) and U.S. (2), and its prev-
alence is increasing, owing to the aging
f the population (3,4). The best current treatment
or organic MR remains uncertain (1,5,6). Studies
rom a single North American institution under-
ined the unfavorable prognosis of organic MR and
he therapeutic potential of early surgical treatment
7–11). By contrast, a single-center European study
from Austria) (12) recently indicated that asymp-
omatic severe MR has a favorable prognosis under
atchful nonsurgical management, raising pro-
ound uncertainties about the natural history of the
isease and the real need for “prophylactic surgery.”
See page 142
These conflicting results have major im-
plications, because the American and Eu-
ropean guidelines for the management of
valvular heart disease are becoming more
liberal, and mitral valve (MV) repair can
now be considered in non-symptomatic pa-
tients with normal ventricular function (1,6).
Because single-center studies might reflect
institutional referral patterns rather than
disease-specific outcomes, multicenter stud-
ies are needed to generate information ap-
plicable to everyday clinical practice.
The MIDA (Mitral Regurgitation In-
ternational DAtabase) was set up specifi-
cally to facilitate multicenter study of the
medical and surgical outcome of MR in
routine clinical practice, and therefore all
consecutive patients were enrolled irre-
pective of baseline characteristics. In keeping with
revious studies (7–10) and current guidelines
1,13), participating centers use echocardiographi-
ally diagnosed flail leaflet (see Online Videos 1A
nd 1B) as a model of significant organic MR. In
he present work, we evaluated data from European
IDA centers to investigate in routine practice: 1)
ncidence and predictors of cardiac morbidity and
ortality under nonsurgical management of MR; 2)
ffects of MV surgery; and 3) the impact of the type
f surgery on prognosis.
E T H O D S
tudy design. The MIDA was assembled by sys-
ion
-ematically merging a series of prospectively assem- fled electronic institutional databases, each origi-
ally created to optimize echocardiographic
eporting (MIDA centers and investigators are
isted in the Appendix). For the present analysis, we
onsidered only patients from the 4 European
enters (tertiary centers at university hospitals in
rance [n  2] and Italy [n  2]). All patients
rovided prior informed consent for anonymous
ublication of their clinical data for scientific re-
earch purposes; the study was conducted in accor-
ance with our institutional guidelines, national
egal requirements, and the revised Helsinki
eclaration.
Patients were screened for the study if they had
egenerative MR with flail leaflet diagnosed with
he use of two-dimensional echocardiography be-
ween 1988 and 2004 at 1 of the participating
enters. Specific eligibility criteria for entry in the
IDA database were: 1) presence of an echocar-
iographically diagnosed flail leaflet according to
alidated criteria (7,14); 2) availability of a compre-
ensive clinical/instrumental evaluation at the time
f baseline echocardiography; 3) exclusion of isch-
mic MR (including papillary muscle rupture); and
) absence of significant concomitant aortic valve
isease, congenital diseases or mitral stenosis, and
rior valve surgery.
chocardiography. All index transthoracic echocar-
iograms were performed within routine clinical
ractice, with standard methods (15), and prospec-
ively entered in each of the original institutional
atabases. Severity of MR was assessed semi-
uantitatively on a scale from 1 to 4 by Doppler
chocardiography (7–10,16,17). Diagnosis of flail
eaflet was based on the failure of leaflet cooptation,
ith rapid systolic movement of the involved leaflet
ip in the left atrium (7,14).
ollow-up. Follow-up collection started in January
004 and was completed in December 2004 in 384
98%) patients. Overall follow-up extended from
aseline evaluation until study closure or last available
ontact (or death). During follow-up, patients were
onitored by their referring physicians. The following
dverse events were recorded: onset of new atrial
brillation (AF) (with electrocardiographic evidence);
eart failure (HF); total mortality; and cardiovascular
eath (CVD). Clinical variables were obtained by
eview of medical records. Events were ascertained by
linical interviews and/or by telephone calls with
hysicians, patients, and (if necessary) next of kin.
utopsy records and death certificates were consultedB B R E V I A T I O N S
N D A C R O N YM S
F atrial fibrillation
I confidence interval
VD cardiovascular death
F heart failure
R hazard ratio
V left ventricular
VEF left ventricular eject
raction
VESD left ventricular end
ystolic diameter
Rmitral regurgitation
Vmitral valve
YHA New York Heartor attribution of cause of death.
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135tatistical analysis. Continuous variables are ex-
ressed as mean  1 SD and/or as median values
25th to 75th percentile). Categorical data are
eported as numbers (percentages). Group compar-
sons were performed with the t test or chi-square
est, as appropriate. Event rates were estimated by
he Kaplan-Meier method and (for descriptive pur-
oses) with linearized yearly rates. Event rates
nder nonsurgical management were calculated
onsidering the entire follow-up of those patients
ho did not undergo MV surgery or the period
rom baseline to any MV operation (as appropriate).
ates of new AF were calculated with data from
atients in sinus rhythm at baseline. We assessed
he global incidence of typical MR-related events in
erms of new AF, HF, or CVD (composite end
oint; of note, patients who had AF at baseline
ere considered to take into account only their
ontribution to incidence of HF or CVD). Post-
urgical follow-up started at the time of the inter-
ention and included the immediate post-surgical
hase (unless otherwise reported).
Cox proportional hazards analysis was used to
ssess predictors of events under nonsurgical man-
gement; variables reaching p  0.10 were entered
n a multivariate model, and hazard ratios (HRs)
ere calculated with 95% confidence intervals
CIs). To assess the influence of surgery on out-
ome, we considered the overall follow-up and
erformed time-dependent proportional hazards
nalysis within multivariate models including all
aseline predictors of events.
All tests were performed with StatView 5.0.1
oftware (SAS Institute Inc., Cary, North Carolina)
or Windows; a value of p 0.05 was considered as
ignificant.
E S U L T S
tudy population. The eligibility criteria were ful-
lled by 394 patients, whose characteristics are
ummarized in Table 1. The majority of patients
resented with no or minimal symptoms and nor-
al ventricular function. The low prevalence of
oronary artery disease (9%) is consistent with the
rganic etiology of the regurgitation. Flail leaflet
as attributable exclusively to a degenerative pro-
ess in 357 (91%) patients and to endocarditis in the
emaining 37 (9%). Involvement was confined to
he posterior leaflet in 314 (79%) patients and to the
nterior leaflet in 31 (8%) and was nonspecified in 3
1%); both leaflets were involved in 46 (12%).Mean overall duration of follow-up was 4.6 
.1 years (median, 3.9 years; interquartile range, 2.2
o 6.5 years). Forty-four deaths were recorded; 32
ere CVD. Estimated overall survival at 5 and 10
ears was 89  2% and 77  4%, respectively.
utcome under nonsurgical management. During a
ean nonsurgical management of 1.4  2.3 years
median, 0.4; interquartile range, 0.1 to 1.4 years),
4 patients died, 24 had new onset AF, and 40 had
F. Causes of death were left ventricular (LV)
ysfunction (n  8), unexplained sudden death (n
2), coronary artery disease (n  1), and noncar-
iac (n  3). Estimated overall survival was 86 
% at 5 years. Table 2 reports numbers, linearized
ates, and estimated 5-year incidence of adverse
vents during nonsurgical management, and Figure
depicts estimated 8-year cumulative incidence of
dverse events.
In univariate analysis, the following baseline
ariables reached at least a trend (p  0.10) toward
ssociation with adverse cardiac events (AF, HF, or
Table 1. Baseline Characteristics of 394 Patients With MR Due
to Flail Leaﬂet
Age (yrs) 64  11
Male gender 265 (67%)
NYHA functional class III–IV 142 (36%)
Sinus rhythm 325 (83%)
History of coronary artery disease 33 (9%)
Left atrial dimension (mm) 48  8
Left ventricular end-diastolic dimension (mm) 59  8
Left ventricular end-systolic dimension (mm) 35  7
Left ventricular ejection fraction (%) 67  10
Grade 3–4 MR by Doppler echocardiography 381 (97%)
Vasodilators 236 (60%)
Beta-blockers 73 (19%)
Digoxin 95 (24%)
Diuretics 199 (51%)
MR  mitral regurgitation; NYHA  New York Heart Association.
Table 2. Numbers, Linearized Rates, and 5-Year Estimated
Incidence of Events in Patients With MR Due to Flail Leaﬂet
During Nonsurgical Management
Event Events n (%) Linearized Rates
5-Yr
Incidence
New-onset AF* 24 (8%) 5.4%/yr 25 5%
HF 40 (10%) 8.0%/yr 39 6%
Total mortality 14 (4%) 2.6%/yr 14 4%
HF/CVD 46 (12%) 9.3%/yr 42 6%
AF/HF/CVD 59 (15%) 12.4%/yr 51 6%
*In patients in sinus rhythm at baseline (n  325).
AF atrial ﬁbrillation; CVD cardiovascular death; HF heart failure; MRmitral regurgitation.
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136VD): age (p  0.001), New York Heart Associ-
tion (NYHA) functional class III to IV (p 
.001), renal insufficiency (p  0.001), left ventric-
lar end-systolic diameter (LVESD) (p  0.016),
nd left ventricular ejection fraction (LVEF) (p 
.002). With Cox proportional hazards analysis,
ndependent predictors of cardiac events were age
adjusted HR/year 1.03, 95% CI 1.01 to 1.05; p 
.025); NYHA functional class (adjusted HR for
lass III to IV 2.93, 95% CI 1.62 to 5.32; p 
.001), and LVEF (adjusted HR/% 0.96, 95% CI
.93 to 0.98; p  0.001). Notably, right ventricular
ystolic pressure (p 0.48) and LVESD (p 0.73)
id not retain independent significance.
urgery and post-surgical outcome. The MV surgery
as performed in 315 (80%) patients, on the basis
f the following indications: dyspnea/HF in 215
68%), “prophylactic surgery” in 47 (15%), LV
ilation in 19 (6%), endocarditis in 13 (5%), iso-
ated AF in 1, and various other factors in the
emaining 20 (6%).
The median time (25th to 75th percentile) from
he baseline echocardiogram to the MV operation
as 2 (1 to 8) months. Estimated combined inci-
ence of MV surgery/CVD at 8 years was 87  2%
verall (Fig. 1). Of note, patients who did not
ndergo surgery had severe symptoms at baseline
ess often (NYHA functional class III to IV: 13 of
9 [16%] vs. 129 of 315 [41%]; p  0.001) but, in
omparison with the other patients, did not display
2 4 6 81
D 115 82 59 47 34 29 19 13
112 75 55 37 27 23 15 12
97 68 47 36 28 24 16 11
3 5 7 Years
MV surgery/CVD
HF 50 ± 7 %
AFib
30 ± 7 %
87 ± 2 %
Outcome of Mitral Regurgitation Due to Flail Leaﬂet Under
owing the estimated 8-year cumulative incidence of atrial ﬁbrilla-
e (HF), or mitral valve (MV) surgery/cardiovascular death (CVD)
nagement of patients (n  394) with mitral regurgitation due to
indicate that patients experienced high rates of adverse events
agement, and surgery seemed almost unavoidable at 8 years.tatistically significant differences in terms of age e66  13 years vs. 64  11 years; p  0.095),
VEF (66  8% vs. 67  9%; p  0.4), renal
nsufficiency (6 of 79 [8%] vs. 15 of 315 [5%]; p 
.4), diabetes (5 of 79 [7%] vs. 27 of 315 [9%]; p 
.6), or pulmonary disease (10 of 79 [13%] vs. 31 of
15 [10%]; p  0.5).
During a mean post-surgical follow-up of 4.1 
.8 years (median, 3.5 years; interquartile range, 1.8
o 5.9 years), 30 patients died. Causes of death were
V dysfunction (n  11), thromboembolisms/
leeding (n  5), coronary artery disease (n  3),
nfective endocarditis (n  2), and noncardiac (n 
). Perioperative mortality (defined as death within
0 days of the operation) was 0.7% (n  2).
stimated overall survival after MV surgery was 89
2% at 5 years and 79  5% at 10 years. At
ultivariate analysis, surgery performed during
ollow-up was associated with a reduced risk of
dverse cardiac events independently of age,
YHA functional class, and LVEF (Fig. 2).
The surgical procedure could be ascertained in all
ut 2 patients. The MV was repaired in 250 (80%)
atients and replaced in 63 (20%). In 35 (11%)
atients, a coronary artery bypass graft was also
erformed during MV surgery. At baseline, patients
ho underwent MV replacement were on average
lder than those who had MV repair (66 10 years
s. 64 11 years, p 0.089), more often presented
onfined anterior leaflet involvement (13% vs. 6%, p
0.068), and more often had AF (29% vs. 15%, p
0.013). No significant difference between pa-
ients who received MV repair or replacement was
ound in terms of baseline mean LVEF or preva-
ence of NYHA functional class III to IV (both p
.49). The mean time from the echocardiogram to
urgery was longer in patients who eventually un-
erwent MV replacement (16  27 months vs. 7 
7 months, p  0.002). Table 3 reports numbers
linearized rates) and estimated 5-year incidence of
dverse events during post-surgical follow-up ac-
ording to surgical strategy. Estimated 5-year over-
ll survival was 92  2% in patients who had MV
epair and 80  6% in those submitted to MV
eplacement (p  0.001). As can be seen from
igure 3, after adjusting for age, LVEF, end-
iastolic diameter, and NYHA functional class,
V repair remained associated with remarkably
etter outcomes.
ubgroup analysis of asymptomatic patients with nor-
al ventricular function. In light of current guide-
ines (1,6) and the finding that severe symptoms
nd LV dysfunction were predictors of adverse0
0
MV surgery/CV
HF 
Afib 
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Kaplan-Meier curves sh
tion (AFib), heart failur
during nonsurgical ma
ﬂail leaﬂet. The resultsvents in this and other (7) study populations, we
a
p
t
f
1
s
p
t
m
w
4
c
w
7
M
o
c
5
w

c
m
t
r
e
r
a
s
i
0
D
T
o
e
a
r
o
P
b
i
M
u
d
O
m
A
s
e
t
b
t
l
v
c
p
o
b
9
w
n
c
e 1.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 1 , N O . 2 , 2 0 0 8
M A R C H 2 0 0 8 : 1 3 3 – 4 1
Grigioni et al.
Multicenter Study on Mitral Regurgitation
137lso evaluated clinical outcome in the subgroup of
atients (n  102) who presented with neither of
hese risk factors. The age of patients in NYHA
unctional class I and with LVEF 60% was 60 
3 years; 79 (78%) were men, 93 (92%) were in
inus rhythm, and 99 (98%) did not show signs of
ulmonary hypertension (i.e., pulmonary artery sys-
olic pressure 50 mm Hg [6]). Under nonsurgical
anagement, the 5-year survival of these patients
as 97  3%. Linearized yearly event rates were
.0% for AF, 5.7% for HF, and 0.4% for CVD. The
ombined incidence of AF, HF, or CVD at 5 years
as 42  8%.
Mitral valve surgery was eventually performed in
0 (69%) patients after a median of 6 months. The
V was repaired in 57 (82%) and replaced in the
ther 13 (18%). No perioperative death was re-
orded. Survival 5 years after MV surgery was 90 
% (100% after MV repair). Patients who under-
ent MV surgery within 12 months of baseline (n
49) showed a lower risk of adverse events when
ompared with the patients assigned initially to
edical management (n  53, of which 21 even-
ually had surgery) (Fig. 4). Of note, although the
elative risk of CVD was much lower than 1 with
arly surgical management, this end point did not
each statistical significance. Estimated 5-year over-
ll survival was 100% in patients who underwent
urgery within 12 months and 96  3% in those
nitially assigned to medical management (p 
.39).
I S C U S S I O N
o our knowledge, this is the first multicenter study
n the long-term outcome of MR diagnosed by
chocardiography under nonsurgical management
nd during post-surgical follow-up. Whereas the
esults of nonsurgical management could be a cause
f concern, those after MV repair seem reassuring.
atients with flail leaflet had notable cardiac mor-
idity and mortality, despite favorable clinical and
nstrumental parameters at presentation. Benefits of
V surgery were mainly seen in patients who
nderwent MV repair early during the course of the
isease.
utcome under nonsurgical management. Because
ost previous studies of MR derive from a single
merican center (7–11), it was unclear whether
uch a high rate of adverse cardiac events would be
ncountered in clinical practice elsewhere. Varia-
ions are to be expected in patients’ characteristics
etween institutional settings, and differences be-ween health care systems could influence surveil-
ance modalities and therefore limit the external
alidity of results. Remarkably, a recent single-
enter analysis (12) of the outcome of 132 Austrian
atients affected by severe organic MR—only about
ne-half of whom had flail leaflet—recorded a
enign prognosis: at 4 years, overall survival was
6% and survival free from any indicator for surgery
as 78%. These findings question the appropriate-
ess of prophylactic surgery, as contemplated in the
urrent guidelines (1,6). The present analysis of
Figure 2. Independent Associations Between MV Surgical Treatm
in 394 Patients With Flail Leaﬂet
Time-dependent analysis shows favorable associations between MV
come in patients (n  394) with degenerative MR due to ﬂail leaﬂe
age, New York Heart Association functional class, and left ventricula
The results support the rationale for considering MV surgery early i
disease. Cases of perioperative (i.e., 30 days) AFib (n  24) were e
analysis. Point estimates of hazard ratios (HRs) are graphically depic
their 95% conﬁdence intervals (CI) (lines). Abbreviations as in Figur
Table 3. Numbers of Events in Patients With MR Due to Flail Le
Surgical Follow-Up and 5-Year Incidence (Linearized Rates) Acco
Surgical Procedure
Event n (%)
5-Yr Incidence (Line
Replacement
(n  63)
Total mortality 30 (10%) 20 6% (5.3%/yr)
CVD 21 (7%) 16 5% (4.6%/yr)
HF 29 (10%) 6 3% (2.2%/yr)
HF/CVD 46 (15%) 21 6% (6.3%/yr)
*Difference statistically signiﬁcant (i.e., 0.05) between mitral valve repair versent and Outcome
surgery and out-
t (after adjusting for
r ejection fraction.
n the course of the
xcluded from the
ted as circles, withaﬂet During Post-
rding to Type of
arized Rates)
Repair
(n  250)
8 2% (1.5%/yr)*
6 2% (0.8%/yr)*
13 3% (2.5%/yr)
16 3% (3.2%/yr)*
us replacement.
Abbreviations as in Table 2.
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138ata pooled from several European centers was
ased on a larger sample size (12). We found a total
nnual mortality under medical treatment ap-
roaching 3%, with notable linearized annual rates
f AF (5.4%) and HF (8.0%) (Table 2). Thus, MR
ue to flail leaflet seemed to be associated with
erious morbidity and mortality (Fig. 1). This
tudy’s focus on routine clinical practice implied
nclusion of all consecutive patients with MR.
ecause the inclusion of patients meeting consensus
uidelines for surgery might conceivably have con-
ributed to the high incidence of events under
onsurgical management (ultimately leading to an
verestimate of the related risks), we also performed
subgroup analysis of lower-risk patients. Remark-
bly, adverse cardiac events were also rather com-
on among asymptomatic patients who presented
ith normal ventricular function (freedom from
VD or any indication for surgery at 5 years was
nly 58%).
The MIDA registry has the advantage of taking
ail leaflet as a model of pure, severe chronic MR
7–10). As well as being a specific sign of severe
R according to current guidelines (1,13), flail
eaflet is a frequent cause of surgical MR (3,4,7,13).
tudies using different models of MR have gener-
ted highly variable 5-year survival figures (ranging
rom 27% to 97%) (7). In addition to sample size
onsiderations (18–22), discrepancies can also be
elated to enrolment of patients with varying de-
rees of regurgitation (18,23,24). Of note, patients
nrolled in the Austrian series (12) had generally
maller ventricular dimensions (likely reflecting less
evere consequences of MR) than the present co-
ort. The favorable outcome recorded in the Aus-
rian study (12) might also be related to the signif-
cantly younger mean age of the patients (55  15
ears). The mean age of the present study popula-
ion (64  11 years) is consistent with the demo-
raphic data of patients enrolled in the large Euro
eart Survey on Valvular Heart Disease (mean age
4  14 years) (4) and therefore likely provides a
etter reflection of current routine clinical practice.
urgery and post-surgical outcome. In the present
tudy, MV surgery generally seemed to be almost
nevitable in the medium term (Fig. 1). Interest-
ngly, the proportion of surgical interventions that
ould be considered “prophylactic” was rather sim-
lar to that reported in the European survey (4),
ikely reflecting a growing awareness of the severity
f natural history of MR. The MV surgery per-
ormed during follow-up was independently asso-Figure 3. Independent Associations Between Surgical Strategy and Outcome in
313 Patients With Flail Leaﬂet Undergoing MV Surgery
Time-dependent analysis shows favorable associations between MV repair (vs. replace-
ment) and outcome in patients (n  313) with degenerative MR due to ﬂail leaﬂet (after
adjusting for age, New York Heart Association functional class, and left ventricular end-
diastolic diameter and ejection fraction). Mitral valve repair currently seems to be the
strategy of choice in degenerative MR. Point estimates of HRs are graphically depictedFigure 4. Independent Associations Between Therapeutic Strategy and Outcome in
102 Asymptomatic Patients With LVEF >60%
Time-dependent analysis in asymptomatic patients with normal ventricular function (n
 102) (after adjusting for age) shows favorable associations between prompt surgery
(vs. no or delayed surgery) and HF and the combined end point HF/CVD (only CVD
failed to reach statistical signiﬁcance). Mitral valve repair in asymptomatic patients with
normal ventricular function seems to prevent cardiac morbidity. Prompt surgery was
deﬁned as an operation performed 12 months after echocardiography (delayed sur-
gery as 12 months). Point estimates of HRs are graphically depicted as circles, withiated with a reduced risk of total mortality (p 
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139.014), CVD (p  0.018), HF/CVD (p  0.001),
nd AF/HF/CVD (p  0.003) (Fig. 2). Notably,
arly surgical treatment was also associated with a
educed risk of cardiac morbidity in non-
ymptomatic patients with normal ventricular func-
ion (Fig. 4). This is, to our knowledge, the first
ulticenter study to provide evidence of the bene-
ts of MV surgery (25–27). Although previous
ingle-center studies indicated that early surgical
reatment might be warranted, the specific charac-
eristics of the setting raised uncertainties on the
pplicability of the surgical results to clinical prac-
ice elsewhere (28,29). In the present series, the
perative mortality (defined as death within 1
onth of the operation) was 1%, a finding in line
ith a recent survey by the European Society of
ardiology (4). This reassuring figure might be
elated to the patients’ generally favorable clinical/
nstrumental parameters at the time of the inter-
ention and the large proportion of MV repairs. Of
ote, no perioperative death was recorded among
symptomatic patients with normal ventricular
unction. Taken together, these findings seem to
upport early consideration of surgery, before aging
nd hemodynamic deterioration can increase the
urgical risk.
We found that the cardiac surgeon was able to
epair the MV in 80% of cases. The feasibility of a
epair seems to have been an incentive for earlier
urgical treatment (patients undergoing MV repair
ad more favorable baseline characteristics). Never-
heless, clear benefits of MV repair were also
vident at multivariate analysis (Fig. 3), indicating
hat MV repair is advantageous irrespective of
atients’ baseline characteristics. The lower rates of
dverse events (Table 3) also support the MV repair
trategy. Some evidence exists that the advantages
f MV repair could be driven by favorable effects on
entricular function (25). However, in the present
tudy, the greatest benefits of MV repair were
bserved in nonsymptomatic patients presenting
ormal LV function (who displayed excellent sur-
ival at 5 years).
Can the findings of this study tell us anything
bout optimal timing of MV surgery? Although
ositive results of early surgical treatment might
eem attractive, the potential advantages seem
argely to depend on the ability to achieve MV
epair. In highly selected institutions, MV repair is
uccessful in 90% of cases (27,29), but in the wider
uropean Survey, only approximately 50% of inter-
entions succeeded (4). Whether a policy of refer-
ing patients with severe organic MR to major menters characterized by greater skill in MV repair
nd lower mortality rates (28) is ultimately feasible
nd beneficial remains an open question (1,6).
otably, in the European survey, over 30% of
ecisions to select MV replacement were deter-
ined by lack of locally available MV repair facil-
ties (4).
Because this is not a randomized study, no firm
onclusion can be made regarding whether non-
ymptomatic patients with severe MR and normal
V function should undergo prompt surgical treat-
ent. For instance, 1 selection bias concern could
egard hidden reasons for denying surgery (of note,
e were unable to detect major baseline differences
n comorbidities between surgically and nonsurgi-
ally treated patients). Nevertheless, the results of
his multicenter study do provide suggestive evi-
ence in favor of early consideration of surgery
hen MV repair is feasible. The rationale for such
n approach is based on: 1) the high incidence of
dverse events under medical treatment; 2) the
eneralized necessity of surgery in the medium
erm; 3) the low surgical risk; and 4) the more
avorable long-term outcome when the intervention
s performed in an early phase of the disease.
tudy strengths and limitations. A limitation of the
resent study was that, whereas echocardiographic
ata were prospectively collected, clinical and non-
chocardiographic data were obtained by review of
edical records and supplemented by interviews
nd telephone calls with patients, relatives, and
hysicians. Nevertheless, the consistency of our
esults with previous series enrolling MR due to flail
eaflets (7) argues in favor of the study’s internal
alidity. Quantitative assessment of MR was not
btained, but restriction to patients with flail leaflet
1,13) and the consistency of ventricular diameters
ith previous series enrolling severe MR by quan-
itative assessment (11) suggests effective exclusion
f moderate regurgitation. Of note, incidence of AF
ight have been underestimated in the absence of
outine periodic loop monitor surveillance.
O N C L U S I O N S
n the setting of this multicenter study, nonsurgical
anagement of patients with pure, severe organic
R due to flail leaflet diagnosed by echocardiog-
aphy was associated with a high cardiac morbidity
nd mortality. Surgical treatment of MR seemed to
e almost unavoidable in the medium term and was
enerally safe and beneficial. These considerations
ight be seen to support the role of early surgery.
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140owever, the potential benefits of MV surgery
eemed largely to depend on the ability to repair the
alve, and this observation underlines the extreme
mportance of carefully evaluating feasibility in
ndividual patients.
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